Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5294-5299

  Baheti, Gautam ^a   Kiser, Jennifer J ^b   Havens, Peter L ^c   Fletcher, Courtney V ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DRUG METABOLITE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; TENOFOVIR; TENOFOVIR DIPHOSPHATE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CELL POPULATION; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADENINE; ADOLESCENT; ADULT; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 80054715372     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05317-11     Document Type: Article

References (22)

1. Beal, S., L. B. Sheiner, A. Boeckmann, and R. J. Bauer. 2009. NONMEM user's guides (1989-2009), 2009 ed. Icon Development Solutions, Ellicott City, MD.
2. Cockcroft, D. W., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
3. Dayneka, N. L., V. Garg, and W. J. Jusko. 1993. Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21:457-478. (Pubitemid 24025269)
4. Delahunty, T., L. Bushman, and C. V. Fletcher. 2006. Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 830:6-12. (Pubitemid 41831381)
5. Delahunty, T., L. Bushman, B. Robbins, and C. V. Fletcher. 2009. The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877:1907-1914.
6. Ette, E. I., P. J. Williams, and J. R. Lane. 2004. Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic studies. Ann. Pharmacother. 38:2136-2144. (Pubitemid 40169387)
7. Gagnieu, M. C., et al. 2008. Population pharmacokinetics of tenofovir in AIDS patients. J. Clin. Pharmacol. 48:1282-1288.
8. Goicoechea, M., et al. 2010. Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients. AIDS 24:707-716.
9. Goicoechea, M., et al. 2008. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J. Infect. Dis. 197:102-108. (Pubitemid 351263473)
10. Hawkins, T., et al. 2005. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. 39:406-411. (Pubitemid 41003784)
11. Hirt, D., et al. 2011. Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2). Antimicrob. Agents Chemother. 55:2961-2967.
12. Jonsson, E. N., and M. O. Karlsson. 1999. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64. (Pubitemid 29049052)
13. Jullien, V., et al. 2005. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob. Agents Chemother. 49:3361-3366. (Pubitemid 41060583)
14. Kearney, B. P., J. F. Flaherty, and J. Shah. 2004. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet. 43:595-612. (Pubitemid 38951802)
15. King, T., et al. 2006. Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 843:147-156. (Pubitemid 44636410)
16. Kiser, J. J., et al. 2008. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin. Pharmacol. Ther. 83:265-272.
17. Kiser, J. J., et al. 2008. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 52:631-637. (Pubitemid 351170838)
18. Pruvost, A., et al. 2005. Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 49:1907-1914. (Pubitemid 40631606)
19. Pruvost, A., et al. 2009. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob. Agents Chemother. 53:1937-1943.
20. Robbins, B. L., R. V. Srinivas, C. Kim, N. Bischofberger, and A. Fridland. 1998. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl) adenine (PMPA), Bis(isopropyloxymethylcarbonyl) PMPA. Antimicrob. Agents Chemother. 42:612-617. (Pubitemid 28114817)
21. Sharma, A., and W. J. Jusko. 1996. Characterization of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 24:611-635. (Pubitemid 27406370)
22. Vourvahis, M., et al. 2008. The pharmacokinetics and viral activity of tenofovir in the male genital tract. J. Acquir. Immune Defic. Syndr. 47:329-333. (Pubitemid 351619418)